Barclays restated their sell rating on shares of ReWalk Robotics (NASDAQ:RWLK) in a research note published on Friday, March 9th. The firm currently has a $1.00 price objective on the medical device company’s stock.
A number of other analysts also recently weighed in on the stock. ValuEngine raised shares of ReWalk Robotics from a strong sell rating to a sell rating in a research report on Friday, February 2nd. Piper Jaffray reissued a buy rating and set a $3.00 price target on shares of ReWalk Robotics in a research report on Sunday, January 7th. Zacks Investment Research cut ReWalk Robotics from a buy rating to a hold rating in a research note on Thursday, January 4th. Finally, Oppenheimer set a $3.00 price objective on ReWalk Robotics and gave the stock a buy rating in a research note on Monday, January 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. ReWalk Robotics presently has an average rating of Hold and an average target price of $2.58.
RWLK traded down $0.05 on Friday, reaching $1.05. 98,179 shares of the company’s stock were exchanged, compared to its average volume of 269,838. The company has a market cap of $33.01, a PE ratio of -1.11 and a beta of 0.56. ReWalk Robotics has a twelve month low of $1.05 and a twelve month high of $3.20. The company has a debt-to-equity ratio of 2.41, a quick ratio of 1.78 and a current ratio of 2.15.
ReWalk Robotics (NASDAQ:RWLK) last issued its quarterly earnings data on Thursday, March 8th. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.06. ReWalk Robotics had a negative net margin of 318.81% and a negative return on equity of 678.44%. The company had revenue of $1.52 million during the quarter, compared to the consensus estimate of $1.76 million.
An institutional investor recently raised its position in ReWalk Robotics stock. Advisor Group Inc. lifted its stake in shares of ReWalk Robotics (NASDAQ:RWLK) by 1,495.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 181,900 shares of the medical device company’s stock after purchasing an additional 170,500 shares during the quarter. Advisor Group Inc. owned about 0.82% of ReWalk Robotics worth $264,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://theenterpriseleader.com/2018/04/02/rewalk-robotics-rwlk-receives-sell-rating-from-barclays.html.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.